CLE Clinical Trials

1,872 recruitingLast updated: May 21, 2026

There are 1,872 actively recruiting cle clinical trials across 89 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Boston, Massachusetts, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


CLE Trials at a Glance

1,872 actively recruiting trials for cle are listed on ClinicalTrialsFinder across 6 cities in 89 countries. The largest study group is Not Applicable with 666 trials, with the heaviest enrollment activity in New York, Boston, and Houston. Lead sponsors running cle studies include Novartis Pharmaceuticals, M.D. Anderson Cancer Center, and Mayo Clinic.

About CLE Clinical Trials

Looking for clinical trials for CLE? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new CLE trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about CLE clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 1,872 trials

Recruiting
Phase 2

Study of COYA 302 for the Treatment of ALS

Amyotrophic Lateral Sclerosis(ALS)
Coya Therapeutics120 enrolled25 locationsNCT07161999
Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting

Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults

Muscle WeaknessProblems Moving Their Arms and Legs
National Institutes of Health Clinical Center (CC)23 enrolled1 locationNCT06998134
Recruiting
Phase 2

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Stage I Bladder Cancer AJCC v8Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
National Cancer Institute (NCI)160 enrolled129 locationsNCT06770582
Recruiting
Phase 2Phase 3

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Muscle Invasive Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma AJCC v7Muscle Invasive Renal Pelvis Urothelial Carcinoma+4 more
National Cancer Institute (NCI)992 enrolled495 locationsNCT05987241
Recruiting
Phase 3

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals300 enrolled3 locationsNCT07498426
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 1

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC23 enrolled5 locationsNCT07290062
Recruiting

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Primary Sclerosing Cholangitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)143 enrolled1 locationNCT04685200
Recruiting
Not Applicable

Biofeedback-Assisted Pelvic Floor Rehabilitation for Radiation-Induced Sexual Dysfunction in Cervical Cancer Survivors

Cervical CancerFemale Sexual Dysfunction (FSD)Radiation Induced Pelvic Floor Muscle Dysfunction
Beni-Suef University60 enrolled1 locationNCT07597083
Recruiting
Phase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled102 locationsNCT06846281
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled187 locationsNCT07225504
Recruiting
Not Applicable

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

Relapsing Remitting Multiple Sclerosis
SetPoint Medical Corporation60 enrolled6 locationsNCT06796504
Recruiting
Phase 3

Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)

Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled754 locationsNCT07157774
Recruiting
Phase 2

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

Acute Myeloid LeukemiaMyelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive+11 more
M.D. Anderson Cancer Center508 enrolled1 locationNCT02115295
Recruiting
Phase 1

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent High Risk Myelodysplastic Syndrome+4 more
M.D. Anderson Cancer Center38 enrolled1 locationNCT03896269
Recruiting
Phase 1

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Soft Tissue SarcomaMelanomaCarcinoma+13 more
St. Jude Children's Research Hospital48 enrolled1 locationNCT04897321
Recruiting

Genetic Study of Amyotrophic Lateral Sclerosis in Norway

Amyotrophic Lateral Sclerosis
Sykehuset Telemark1,200 enrolled17 locationsNCT05119387
Recruiting
Phase 2

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8
National Cancer Institute (NCI)111 enrolled141 locationsNCT07061964
Recruiting
Not Applicable

Impact of NMES and HPRO on Recovery After SAH- Pilot Study

InflammationSubarachnoid HemorrhageMuscle Atrophy+1 more
University of Maryland, Baltimore30 enrolled1 locationNCT03201094